Marijke Vroomen Durning, RN


How Durable Are CAR T-Cell Therapies?

March 1st 2018

The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.

HCC Therapies Rapidly Advance After a Decade of Disappointment

September 3rd 2017

After a decade of little movement in the treatment of advanced hepatocellular carcinoma (HCC), there are promising developments on the horizon, according to recent study findings.

Secondary Malignancies: Who Is at Risk and Why?

April 20th 2017

As the population of cancer survivors has grown, so has the risk that patients will develop— and succumb to—a second cancer.

New Take on an Old Problem: Tackling VTE With Biomarkers, Risk Models, and Novel Drugs

March 1st 2017

Despite advances in the oncology field, venous thromboembolism remains a significant problem for patients with cancer.

Moving the Meter on Ovarian Cancer

December 2nd 2016

Ovarian cancer remains a silent and deadly tumor type with 5-year survival rates that lag far behind those of other gynecologic malignancies. Yet optimism is in the air these days as researchers focus on developing new therapies in 2 key areas: antiangiogenic agents and PARP inhibitors.

Why CRISPR Gene-Editing Technology Is Captivating Research Field

August 17th 2016

Although researchers have been exploring gene editing for more than 40 years, scientists say the CRISPR technology offers game-changing methods for anticancer research as well as a host of other applications.

The RAS Chase: Gaining Ground Against the Toughest Oncogene

May 24th 2016

The RAS family of genes, implicated in more than 30% of human cancers, has proved to be such a difficult molecular driver to target that researchers have considered it "undruggable." A 3-year-old effort by the National Cancer Institute aims to change that—and is making headway.

Getting to Zero: MRD Yardstick for Myeloma Inches Closer

January 29th 2016

Researchers and oncologists are excited about the prospect of MRD becoming equally useful in the assessment and management of patients with multiple myeloma, particularly in light of the development of new, more effective therapies and the current limited ability to assess their effectiveness.